1例哌拉西林他唑巴坦治疗肺脓肿患者致药物热及横纹肌溶解症药学监护

doi:10.19803/j.1672-8629.2022.04.23

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (4): 450-452.
DOI: 10.19803/j.1672-8629.2022.04.23

1例哌拉西林他唑巴坦治疗肺脓肿患者致药物热及横纹肌溶解症药学监护

杜婧¹,李永辉²,阎纳新¹,郭立杰¹,刘洋^3*

¹石家庄市第五医院临床药学科，河北石家庄 050021；
²河北省药品监测评价中心，河北石家庄 050000;
³石家庄市第四医院临床药学科，河北石家庄 050011

收稿日期:2021-01-22 出版日期:2022-04-15 发布日期:2022-04-15
通讯作者: ^*刘洋,男,硕士,副主任药师,临床药学。E-mail：liuyang4565482005@163.com
作者简介:杜婧,女,硕士,副主任药师,临床药学及不良反应。
基金资助:
石家庄市科学技术研究与发展指导计划项目（161460903）

Pharmaceutical care of a patient with lung abscess with drug fever and rhabdomyolysis induced by piperacillin-tazobactam

DU Jing¹, LI Yonghui², YAN Naxin¹, GUO Lijie¹, LIU Yang^3,*

¹Department of Clinical Pharmacy, the Fifth Hospital of Shijiazhuang, Shijiazhuang Heibei 050021, China;
²Hebei Drug Monitoring and Evaluation Center, Shijiazhuang Heibei 050000, China;
³Department of Clinical Pharmacy, the Fouth Hospital of Shijiazhuang City, Shijiazhuang Heibei 050000, China

Received:2021-01-22 Online:2022-04-15 Published:2022-04-15

摘要/Abstract

摘要： 目的探讨哌拉西林他唑巴坦治疗肺脓肿患者治疗发生药物热及横纹肌溶解症的原因,为临床合理用药提供参考。方法回顾1例临床药师监护肺脓肿患者治疗过程,检索相关文献,结合患者情况探讨哌拉西林他唑巴坦及莫西沙星发生不良反应的原因及临床应用的安全性。结果使用抗菌药物尤其是β-内酰胺类如哌拉西林他唑巴坦时,如体温突然上升要考虑药物热可能;莫西沙星致横纹肌溶解症可能与其化学结构特点有关,需注意控制药品输注速度,如发生不良反应,应及时停药。结论临床应重视抗感染治疗可能发生的药品不良反应,临床药师积极查阅文献等证据,可为临床用药治疗安全有效提供支持。

关键词: 哌拉西林他唑巴坦, 莫西沙星, 药物热, 横纹肌溶解症, 药学监护, 药品不良反应

Abstract: Objective To explore the causes of drug fever and rhabdomyolysis among patients with lung abscess during anti-infective treatment so as to provide reference for clinical rational use of drugs. Methods The process of monitoring one patient with lung abscess by a clinical pharmacist was retrospectively analyzed, related literature was retrieved, and the causes of adverse reactions of piperacillin-tazobactam and moxifloxacin as well as ways of safe clinical application with reference to the patient's condition were discussed. Results When antibiotics were used, especially β -lactams such as piperacillin and tazobactam, the likelihood of drug fever should be considered if the body temperature rose suddenly. Rhabdomyolysis caused by moxifloxacin might have been related to its chemical structure, so infusion speed had to be controlled and the drug withdrawn in time in case of adverse reactions. Conclusion Clinicians should be alert to the adverse drug reactions that may occur during anti-infective treatment. Clinical pharmacists are expected to consult literature to find evidence for the safety and effectiveness of clinical medication.

Key words: piperacillin-tazobactam, moxifloxacin, drug fever, rhabdomyolysis, pharmaceutical care, adverse drug reaction

中图分类号:

R97R994.11

杜婧,李永辉,阎纳新,郭立杰,刘洋. 1例哌拉西林他唑巴坦治疗肺脓肿患者致药物热及横纹肌溶解症药学监护[J]. 中国药物警戒, 2022, 19(4): 450-452.

DU Jing, LI Yonghui, YAN Naxin, GUO Lijie, LIU Yang. Pharmaceutical care of a patient with lung abscess with drug fever and rhabdomyolysis induced by piperacillin-tazobactam[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 450-452.

参考文献

[1] CHEN HZ. Practical Internal Medicine(实用内科学)[M]. 11th ed. Beijing: People’s Medical Publishing House, 2001: 1590-1593.
[2] MAO XG, ZHOU H, ZHANG YY, et al.Research on drug fever caused by β-lactam antibiotics[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2016, 33(6): 822-824.
[3] LI QX. Analysis of a case of drug fever caused by piperacillin and tazobactam sodium[J]. Gansu Medical Journal(甘肃医药), 2019, 38(12): 1134, 1141.
[4] WANG CR.A retrospective analysis of drug fever caused by piperacillin sodium and tazobactam sodium for injection[J]. Chin Hosp Pharm J(中国医院药学杂志), 2019, 39(22): 2334-2337.
[5] LI F, LIAO YF, YAN JH.Clinical pharmacist participating in the anti-infection treatment of one patient with drug fever caused by piperacillin-tazobactam[J]. China Pharmaceuticals(中国药业), 2020, 29(2): 48-51.
[6] WANG CR.Retrospective analysis of 29 cases of drug fever caused by piperacillin sodium and tazobactam sodium for injection[J]. Chin Hosp Pharm J(中国医院药学杂志), 2019, 39(22): 2334-2337.
[7] REN XL, XU P, LI YZ.Rhabdomyolysis related to moxifloxacin in two patients[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2010, 12(3): 217-218.
[8] SONG LQ, ZHANG XJ, ZHANG K.Experts recommendation in management of comorbidities of corona virus disease 2019[J]. Chin J TCM WM Crit Care(中国中西医结合急救杂志), 2020, 27(1): 1-5.
[9] XIAO DD, ZHAO GK, CHEN M.Literature analysis of moxifloxacin-induced adverse drug reactions in 134 cases in China[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2019, 16(5): 287-291,301.
[10] HU Z, CHEN SJ, SU SG, et al.Literature analysis of adverse drug reactions induced by moxifloxacin[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2019, 19(11): 1396-1398, 1402.
[11] ZHANG H, LIU M, LI ZD.One case of rhabdomyolysis induced by moxi?oxacin and literature review[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2015, 12(5): 323-325.
[12] REN XL, ZHANG HY, LI YZ.Pay attention to the safety of clinical medication caused by the adverse reactions of moxifloxacin[J]. Chin Hosp Pharm J(中国医院药学杂志), 2010, 30(23): 2045-2047.
[13] BLANCO JR, ZABALZA M, SALCEDO J, et al.Rhabdomyolysis of infectious and noninfectious causes[J]. South Med J, 2002, 95(5): 542.
[14] SHINTANI S, SHIIGAI T, TSUKAGOSHI H.Marked hypokalemic rhabdomyolysis with myoglobinuria due to diuretic treatment[J]. Eur Neurol, 1991, 31(6): 396.
[15] MOHAPATRA MM, RAJARAM M, MALLICK A.Clinical, radiologicaland bacteriological profile of lung abscess-an observa-tional hospital based study[J]. Open Access MacedJ MedSci, 2018, 6(9): 1642-1646.
[16] “Guiding Principles for the Clinical Application of Antimicrobial Drugs”Revision Working Group. Guidelines for the Clinical Application of Antimicrobial Drugs(抗菌药物临床应用指导原则)[M]. 2015 Ed. Beijing: People’s Medical Publishing House, 2015: 24.

1例哌拉西林他唑巴坦治疗肺脓肿患者致药物热及横纹肌溶解症药学监护

Pharmaceutical care of a patient with lung abscess with drug fever and rhabdomyolysis induced by piperacillin-tazobactam

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.